The first participant has been enrolled in the Progressive Supranuclear Palsy Clinical Trial Platform (PTP), a perpetual platform trial led by the University of California, San Francisco, according to an announcement issued on 7 August 2026 by the non-profit CurePSP. The platform runs on a single master protocol registered as NCT07173803 (study identifier ATRI-015, first posted 15 September 2025), which allows more than one investigational drug to be tested at once and further drugs to be added later without starting a new trial. Two regimen-specific arms are registered: Regimen A, the active tau vaccine AADvac1 from Axon Neuroscience (NCT07217665), and Regimen B, the oral p75 neurotrophin receptor modulator LM11A-31 from PharmatrophiX (NCT07264283). Both registrations name UCSF as sponsor and cite NIA grant R01AG085029.
Under the registered design, a participant first enrols in the master protocol, then, if eligible, is randomised to any regimen open at the time of screening, with an equal chance of each. Each regimen is a double-blind, placebo-controlled comparison with randomisation of three participants on active drug for every one on matching placebo, and the primary outcome in both registered arms is change in disease severity on the 15-item modified Progressive Supranuclear Palsy Rating Scale over 52 weeks. The Regimen B record lists an estimated start of 30 June 2026 and primary completion on 28 September 2030; the Alzforum drug database, a secondary source, records that evaluation of LM11A-31 began in June 2026 and that the arm is to enrol 147 patients on twice-daily drug or placebo. CurePSP says the platform aims to enrol 440 participants over two years at 50 sites, funded by a five-year National Institute on Aging grant of up to 75.4 million dollars, and that 75 per cent of participants receive an active drug in the first year. Registered eligibility includes possible or probable PSP-Richardson's syndrome by the 2017 Movement Disorder Society criteria, symptoms for five years or less, a Mini-Mental State Examination score of 25 or higher, and the ability to walk ten steps with minimal assistance.
Neither drug has shown clinical benefit in PSP, and both enter the platform on evidence generated in Alzheimer's disease. AADvac1 was tested in ADAMANT, a 24-month randomised, double-blind, placebo-controlled phase 2 trial in 196 patients with mild Alzheimer's dementia randomised 3:2, published in Nature Aging in June 2021: the vaccine was safe and immunogenic, and the authors reported no significant differences on clinical outcomes across the whole sample. LM11A-31 was tested in a 26-week randomised, placebo-controlled, double-blind phase 2a trial in 242 people with mild to moderate Alzheimer's disease, published in Nature Medicine in May 2024, whose primary endpoint was safety and tolerability rather than clinical benefit. Enrolling a first participant is a logistical milestone in a trial that has not yet reported anything, and the registry records for all three postings were last verified in late 2025, when they were still listed as not yet recruiting.
PSP is a rare tauopathy that can resemble Parkinson's disease in its early loss of balance and stiffness, and it has no approved treatment. The platform is modelled on the HEALEY ALS Platform Trial, and CurePSP describes it as the first platform trial in the disease. Adam Boxer of UCSF, the lead principal investigator, said in the announcement that the design should increase the number of drugs tested and generate longitudinal data on the causes of the disease. In April 2025 the platform announced AADvac1 and Alzprotect's AZP2006 as the selections for its first two regimens; the arms registered to date are AADvac1 and LM11A-31.